NASDAQ:QNRX Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis $3.56 +0.20 (+5.95%) Closing price 04:00 PM EasternExtended Trading$3.53 -0.03 (-0.79%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Quoin Pharmaceuticals Stock (NASDAQ:QNRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quoin Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.35▼$3.5650-Day Range$3.36▼$7.0652-Week Range$3.25▼$23.50Volume7,033 shsAverage Volume255,952 shsMarket Capitalization$17.09 millionP/E RatioN/ADividend YieldN/APrice Target$17.33Consensus RatingModerate Buy Company Overview Quoin Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin. Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.AI Generated. May Contain Errors. Read More Quoin Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreQNRX MarketRank™: 3.991747637425 of 5 starsQuoin Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 92nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingQuoin Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialQuoin Pharmaceuticals has a consensus price target of $17.33, representing about 398.8% upside from its current price of $3.48.Amount of Analyst CoverageQuoin Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Quoin Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Quoin Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quoin Pharmaceuticals is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuoin Pharmaceuticals has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.53% of the float of Quoin Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverQuoin Pharmaceuticals has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quoin Pharmaceuticals has recently increased by 17.17%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuoin Pharmaceuticals does not currently pay a dividend.Dividend GrowthQuoin Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.37 News SentimentQuoin Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Quoin Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for QNRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Quoin Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying4 insiders have purchased shares of Quoin Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $279,966.00 in company stock, which represents 1.6785% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Quoin Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $279,966.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders7.54% of the stock of Quoin Pharmaceuticals is held by insiders.Percentage Held by Institutions8.63% of the stock of Quoin Pharmaceuticals is held by institutions.Read more about Quoin Pharmaceuticals' insider trading history. Receive QNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNRX Stock News HeadlinesQuoin Pharmaceuticals (NASDAQ:QNRX) Stock Rating Lowered by Wall Street ZenNovember 15 at 10:10 AM | americanbankingnews.comQuoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) Stock Now Rated "Moderate Buy" by Sell-Side AnalystsNovember 13, 2026 | americanbankingnews.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 18 at 1:00 AM | Paradigm Press (Ad)Wall Street Zen Upgrades Quoin Pharmaceuticals (NASDAQ:QNRX) to "Hold"November 7, 2026 | americanbankingnews.comQuoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton SyndromeNovember 6, 2026 | markets.businessinsider.comQuoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton SyndromeNovember 6, 2026 | markets.businessinsider.comQuoin Pharmaceuticals' Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton SyndromeNovember 6, 2026 | globenewswire.comQuoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsNovember 5, 2026 | globenewswire.comSee More Headlines QNRX Stock Analysis - Frequently Asked Questions How have QNRX shares performed this year? Quoin Pharmaceuticals' stock was trading at $14.43 on January 1st, 2026. Since then, QNRX stock has decreased by 75.9% and is now trading at $3.4750. How were Quoin Pharmaceuticals' earnings last quarter? Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.52) by $0.55. When did Quoin Pharmaceuticals' stock split? Quoin Pharmaceuticals shares reverse split on Monday, July 17th 2023.The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Quoin Pharmaceuticals IPO? Quoin Pharmaceuticals (QNRX) raised $0 in an initial public offering on Friday, July 29th 2016. The company issued 1,292,308 shares at $0.00 per share. Who are Quoin Pharmaceuticals' major shareholders? Top institutional shareholders of Quoin Pharmaceuticals include Nantahala Capital Management LLC (4.92%) and AIGH Capital Management LLC (4.92%). Insiders that own company stock include Anthony James Culverwell, Michael Myers, Denise P Carter, Dennis Langer, Sally Bridget Lawlor and Gordon Dunn. View institutional ownership trends. How do I buy shares of Quoin Pharmaceuticals? Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quoin Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quoin Pharmaceuticals investors own include Rivian Automotive (RIVN), AMC Entertainment (AMC), NIO (NIO), Pfizer (PFE), SNDL (SNDL), Tesla (TSLA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/05/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, QNRX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:QNRX CIK1671502 Webquoinpharma.com Phone(703) 980-4182Fax972-9767-8750Employees4Year FoundedN/APrice Target and Rating Average Price Target for Quoin Pharmaceuticals$17.33 High Price Target$20.00 Low Price Target$14.00 Potential Upside/Downside+386.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($19.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.81 million Net MarginsN/A Pretax MarginN/A Return on Equity-227.75% Return on Assets-149.97% Debt Debt-to-Equity RatioN/A Current Ratio7.20 Quick Ratio7.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book0.60Miscellaneous Outstanding Shares4,800,000Free Float4,442,000Market Cap$17.09 million OptionableNot Optionable Beta1.71 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:QNRX) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.